Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

High-dilution germ-killing actives for Lysol and Dettol

Reckitt Benckiser

Reckitt Benckiser (RB) is seeking alternative germ-killing actives to quaternary ammonium for use in Lysol and Dettol that are equally effective at low concentrations, high dilutions, and direct replacement volumes.

RB is a global consumer products company that operates a portfolio of leading household brands in nutrition, health and hygiene, including popular disinfectants Lysol and Dettol. First introduced in 1889, Lysol products can be found in half of all U.S. homes, while Dettol is sold in more than 120 countries. Both Lysol and Dettol come in a variety of formats, from sprays and wipes to soaps and detergents. Over the years, these products have fought germs using a range of active ingredients, including quaternary ammonium, or “quats”. Known for their potency at very low concentrations, quats are effective at killing germs at concentrations of 2.4% and dilutions of 1:125 or more. For this reason, quats remain the active ingredient in laundry detergents, which undergo significant dilution during the wash cycle, while sprays, wipes and other formats have transitioned to alternatives. As consumers demand more natural solutions, we are looking for alternatives.

At RB we strive to give consumers safe and effective solutions to kill all types of germs. With that in mind, we are seeking innovative technologies and approaches that can deliver equal or more effective germ-kill than quats in low concentrations, high dilutions, and at comparable formula volumes and are effective against bacteria, viruses, fungi and/or yeast. Proposed technologies will be assessed based on meeting industry standards, regulatory, cost and supply considerations, and the ability to be used on fabrics without any deleterious effects. Solutions of interest include:

Technologies that fully replace quats
Technologies that use quats at low levels (<1%) in combination with an alternative active ingredient

DEADLINE: OPEN

Specialties

Engineering and Physical Sciences

Medical - Translational

Medical

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: Reckitt Benckiser

Sponsor Type:

Address: NA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity